Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years

Feng, Jianyang; Xu, Lijiang; Chen, Yangping; Lin, Rongjin; Li, Haoxian; He, Hong

doi:10.1186/s13048-023-01233-y

Cited by 16 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While significant strides have been taken in ovarian cancer treatment, its overall survival rate remains low [ 66 ] . The incidence and mortality rates of ovarian cancer in China have exhibited an upward trajectory over the past three decades, with this trend anticipated to persist over the next 30 years [ 67 ].…”

Section: M1a and Cancermentioning

confidence: 99%

Research progress of N1-methyladenosine RNA modification in cancer

Liu,

Zhang,

Gao

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

N1-methyladenosine (m1A) is a post-transcriptionally modified RNA molecule that plays a pivotal role in the regulation of various biological functions and activities. Especially in cancer cell invasion, proliferation and cell cycle regulation. Over recent years, there has been a burgeoning interest in investigating the m1A modification of RNA. Most studies have focused on the regulation of m1A in cancer enrichment areas and different regions. This review provides a comprehensive overview of the methodologies employed for the detection of m1A modification. Furthermore, this review delves into the key players in m1A modification, known as the “writers,” “erasers,” and “readers.” m1A modification is modified by the m1A methyltransferases, or writers, such as TRMT6, TRMT61A, TRMT61B, TRMT10C, NML, and, removed by the demethylases, or erasers, including FTO and ALKBH1, ALKBH3. It is recognized by m1A-binding proteins YTHDF1, TYHDF2, TYHDF3, and TYHDC1, also known as “readers”. Additionally, we explore the intricate relationship between m1A modification and its regulators and their implications for the development and progression of specific types of cancer, we discuss how m1A modification can potentially facilitate the discovery of novel approaches for cancer diagnosis, treatment, and prognosis. Our summary of m1A methylated adenosine modification detection methods and regulatory mechanisms in various cancers provides useful insights for cancer diagnosis, treatment, and prognosis.

show abstract

Section: M1a and Cancermentioning

confidence: 99%

Research progress of N1-methyladenosine RNA modification in cancer

Liu,

Zhang,

Gao

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…The U.S.A has become the biggest stronghold to support ovarian cancer patients against recurrence: It contributed to the most publications with highest betweenness centrality; six of the top 10 institutions carrying out research on ROC treatment were governed by the U.S.A; three authors and six co-cited authors in the ranking lists were American. China was the only developing countries among the top 10 countries with the most publications, since the government has noticed the yearly increased mortality of OC in this region 14 and granted more ndings in this eld. However, the central score was still very low for China, and no authors, institutions or references have been seen in the top 10 lists, suggesting that more original and innovative articles are needed urgently in this country.…”

Section: Contributions Of Countries Institutions and Authorsmentioning

confidence: 99%

Past and present: a bibliometric study on the treatment of recurrent ovarian cancer

Hao,

Li,

Song

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Ovarian cancer (OC) is a gynecological malignancy with high mortality worldwide. The poor prognosis of OC is usually attributed to its recurrence-prone signature. Recently, mortality from OC has exhibited a downward trend. These favorable patterns likely find their main driving factor in advancements in novel therapeutic regimens. However, visualized analysis of the application of these new drugs on women with recurrent OC (ROC) is lacking. Therefore, we aimed to summarize changing paradigms in the ROC treatment using the bibliometric method. Methods Documents on ROC treatment were systematically collected from the MEDLINE database and Web of Science Core Collection (WOSCC). The retrieved documents were exported in the plain text file format, and files were named and saved to the paths specified by the Java application. Microsoft Excel (version 2010), Citespace (6.2.R4) and VOSviewer (1.6.19) were used for data analysis and included the following: (1) annual publication trend; (2) contributions of countries, institutions and authors; (3) co-citation of journals and references; and (4) co-occurrence of keywords. Results A total of 914 documents published in the MEDLINE and 9,980 ones in WOSCC were retrieved. There has been an upward trend in the productivity of publications on ROC treatment on by years. The United States was the leading contributor in this field, and the University of Texas System was the most productive institution. Giovanni Scambia and Maurie Markman were the research leaders for ROC treatment. Gynecologic Oncology was the journal with most citation frequency. The reference entitled with “Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer” got highest centrality of 0.14 in the co-citation network. Keyword analysis indicated that current treatment of ROC mainly focused on the platinum-based anticancer drugs, paclitaxel, angiogenesis inhibitors (AIs) and poly (ADP-ribose) polymerase inhibitors (PARPis). Conclusion Scholars from all over the world have taken active part in the development of ROC treatment. International top journals and professional periodicals on gynecologic oncology have been the main sources of the hotspots and frontiers in this field. Maintenance treatment based on AIs or (and) PARPis has become an important adjunct to chemotherapy based on platinum agents and paclitaxel for ROC patients.

show abstract

“…Ovarian cancer (OC) is one of the three most prevalent and lethal malignancies affecting the female reproductive organs, alongside endometrial and cervical cancers ( 1 ). Its incidence has been increasing worldwide, and it now has the second highest yearly incidence rate among cancers of the female reproductive system ( 2 , 3 ). Epithelial OC (EOC), which constitutes 85 to 90% of all ovarian tumors, is the most common subtype ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Current data and future perspectives on DNA methylation in ovarian cancer (Review)

Fu,

Deng,

Chen

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

Ovarian cancer (OC) represents the most prevalent malignancy of the female reproductive system. Its distinguishing features include a high aggressiveness, substantial morbidity and mortality, and a lack of apparent symptoms, which collectively pose significant challenges for early detection. Given that aberrant DNA methylation events leading to altered gene expression are characteristic of numerous tumor types, there has been extensive research into epigenetic mechanisms, particularly DNA methylation, in human cancers. In the context of OC, DNA methylation is often associated with the regulation of critical genes, such as BRCA1/2 and Ras-association domain family 1A. Methylation modifications within the promoter regions of these genes not only contribute to the pathogenesis of OC, but also induce medication resistance and influence the prognosis of patients with OC. As such, a more in-depth understanding of DNA methylation underpinning carcinogenesis could potentially facilitate the development of more effective therapeutic approaches for this intricate disease. The present review focuses on classical tumor suppressor genes, oncogenes, signaling pathways and associated microRNAs in an aim to elucidate the influence of DNA methylation on the development and progression of OC. The advantages and limitations of employing DNA methylation in the diagnosis, treatment and prevention of OC are also discussed. On the whole, the present literature review indicates that the DNA methylation of specific genes could potentially serve as a prognostic biomarker for OC and a therapeutic target for personalized treatment strategies. Further investigations in this field may yield more efficacious diagnostic and therapeutic alternatives for patients with OC.

show abstract

Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years

Cited by 16 publications

References 25 publications

Research progress of N1-methyladenosine RNA modification in cancer

Research progress of N1-methyladenosine RNA modification in cancer

Past and present: a bibliometric study on the treatment of recurrent ovarian cancer

Current data and future perspectives on DNA methylation in ovarian cancer (Review)

Contact Info

Product

Resources

About